Celcuity Inc. (NASDAQ: CELC) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT CELCUITY INC.

Celcuity Inc. (NASDAQ: CELC)
Listen to this Section


$98.55
+2.6160 ( +2.73% ) 604.7K

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Market Data


Open $98.55
Previous Close $95.93
Volume 604.7K
Market Cap $4.70B
Day Range $94.00 - $101.24
52 Week Range $11.52 - $151.02
Shares Outstanding 48.77M
Change % +2.73%
Net Change ▲ 2.6160
Insider Ownership -0.04%
Exchange NASDAQ
SectorMiscellaneous
IndustryNone
IPO Year2017
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -2,981,087.00

Date Type Amount Purchased Purchaser
2025-09-10 Buy 13976.00 BAKER BROS. ADVISORS LP
2025-09-10 Buy 13976.00 BAKER BROS. ADVISORS LP
2024-06-25 Sale -350.00 Buller Richard E
2024-06-12 Sale -5061.00 NIGON RICHARD
2024-06-06 Sale -8153.00 Murphy Polly A.
2024-06-06 Sale -8153.00 Dalvey David
2024-06-06 Sale -8153.00 Furcht Leo
2024-06-06 Sale -1079.00 Buller Richard E
2024-06-06 Sale -8153.00 NIGON RICHARD
2024-05-24 Sale -1958.00 Buller Richard E

SEC Filings


Form Type Description Pages Date
10-q Quarterly Reports 57 Aug 14, 2025
8-k 8K-related 14 Aug 14, 2025
8-k 8K-related 23 Aug 01, 2025
3 Insider transactions 1 Aug 01, 2025
8-k 8K-related 18 Jul 31, 2025
4 Insider transactions 1 Jul 30, 2025
8-k 8K-related 15 Jul 29, 2025
8-k 8K-related 15 Jul 28, 2025
8-k 8K-related 14 Jun 30, 2025

Latest News